Lethal mutations in pregnancy loss
REYKJAVIK, Iceland , May 21, 2025 /CNW/ -- In a study published in Nature today "Sequence diversity lost in early pregnancy," scientists from deCODE genetics, a subsidiary of Amgen, estimate that around one in 136 pregnancies are lost due to new mutations in the fetus. In other words, millions of pregnancies worldwide are lost because of mutations every year.
The human genome varies between individuals, but there are some locations in the genome where there seems to be little or no sequence variation between individuals. This raises the question whether the sequences at these locations are essential for human development? It is known that mutations in essential genomic sequences are major contributors to neurodevelopmental disorders, the question remains, do they also contribute to pregnancy loss?
As part of a Nordic collaboration, scientists from deCODE genetics sought to answer these questions by sequencing 467 samples from pregnancy losses from a prospective study initiated by Henriette Svarre Nielsen and Eva R. Hoffmann.
Interestingly, by comparing the genomes of the fetuses from pregnancy losses to their parents the scientists found that the fetuses harbored a similar number of new mutations as adults.
"Despite the similar numbers, we discovered that the main difference between the lost fetuses and adults was that the mutations in the fetuses occurred in essential genomic sequences," says Hákon Jónsson scientist at deCODE genetics, and one of the authors on the paper.
Moreover, they managed to pinpoint when, in the development of the fetus, some of the mutations occurred.
In addition to mapping new mutations in the lost fetuses, they also showed that some couples are at a higher risk of pregnancy loss due to genetic compatibility issues. You inherit one copy of a gene from each parent, and most of the time, you are fine with one defective copy, but problems can arise if you inherit a defective copy from both parents.
"We have shown previously that for certain genes, you never observe two defective copies in adult genomes, but we found two defective copies in some of the pregnancy losses. Importantly, these involve a high risk for recurrence of pregnancy loss for the couple but can be selected against in IVF treatments," says Guðný A. Árnadóttir scientist at deCODE genetics, and one of the authors on the paper.
Along with recombination, the continuous generation of mutations enables us to evolve as a species. However, this continuous influx of new mutations comes at the expense of rare diseases. This study demonstrates the contribution of mutations to pregnancy loss and sheds new light on conserved sequences in the human genome.
Based in Reykjavik, Iceland , deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases. The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease. deCODE genetics is a wholly-owned subsidiary of Amgen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
4 days ago
- CBC
Why those suffering miscarriages could benefit from specialized clinics
Bethany Murray experienced two early pregnancy losses last year and wishes the wait for follow-up mental health care had been smoother. Last winter, when Murray was five-weeks pregnant, she realized she was bleeding heavily and rushed to the emergency department. She was devastated to learn the pregnancy was ending. She and her husband tried again months later, but during an ultrasound appointment, she learned her second pregnancy had also ended early. "My brain was just spinning," Murray recalled. "You blame everything on yourself, even though at the end of the day, you finally know there's nothing you did." About 15 per cent of pregnancies end before 14 weeks gestation, according to the Society of Obstetricians and Gynaecologists of Canada (SOGC). Some will suffer early pregnancy loss, commonly called miscarriage, multiple times. Psychological distress such as depression, anxiety and post-traumatic stress disorder are common after such a loss, according to the SOGC. The new guidelines, released at the annual SOGC conference in Whistler, B.C., this week, are designed to improve care for patients. They include: Run early pregnancy assessment clinics, where nurses and physicians offer compassionate care in a private area of the emergency department to women who are under 20 weeks' gestation and experiencing pregnancy complications such as nausea, vomiting, vaginal bleeding, abdominal pain or cramping. Offer the medications used to medically manage miscarriage free of charge to avoid surgery for some first trimester pregnancy losses. Reform mental health screening to check for depression and post-traumatic stress disorder (PTSD) routinely in those diagnosed with pregnancy loss. Provide bereavement counselling and other resources to help women who have suffered early pregnancy loss. "Studies have clearly shown offering compassionate care in a proper way from the beginning can lessen that impact," for long-term complications, said Dr. Lynn Murphy-Kaulbeck, the president of SOGC. WATCH | Trauma-informed care for miscarriages: Post-miscarriage care has been overlooked. New recommendations aim to change that 1 day ago Duration 2:02 All-in-one clinics offer advantages Murray agreed with the recommendations, saying she wished someone had talked with her in the hospital and connected her with support networks. When she did go for mental health counselling, the Whitby, Ont., resident said it was difficult to be in a prenatal clinic waiting room. "I think that there should be a separate room for women that have had early or late pregnancy losses where you're not, you know, sitting in a room full of pregnant women." The SOGC's recommendations include a call for more early pregnancy assessment clinics to be established across the country, similar to ones in Britain. Dr. Modupe Tunde-Byass, an obstetrician and gynecologist who trained in Britain introduced such a clinic at North York General Hospital, where she currently works. She welcomed the recommendation and estimates roughly one-third of hospitals offer similar clinics, which are concentrated in major cities. Murphy-Kaulbeck, the SOGC president, says the recommendations also call for consistent and equitable care, which is especially important for rural areas where the emergency department is often the only option. Early pregnancy loss is still "a condition that nobody talks about," said Tunde-Byass, who is also an associate professor of obstetrics and gynaecology at the University of Toronto. Lasting depression and anxiety Seeing a health-care provider in a welcoming environment with "fine-tuned" care can make a difference to long-term health, Tunde-Byass said. Rather than using a whole new set of resources, the clinics use existing hospital staff and space. At Tunde-Byass's clinic, patients experiencing bleeding, abdominal pain and cramping, are cared for in a private room instead of the emergency department. His wife had a miscarriage, he had no time to grieve. It's a policy he says needs to change 1 month ago Duration 3:28 Etienne Crevier's wife had a miscarriage two weeks ago. He wants grieving fathers-to-be to have access to the same parental insurance benefits to mourn the loss of a child as women do. Having nurses or physicians trained in bereavement counselling or breaking bad news would help in staffing such clinics, Tunde-Byass said. "When you think about depression, post traumatic stress disorders, anxiety, this actually goes on for six to 12 months," Tunde-Byass said, adding that existing children and partners are also impacted. Obstetrician and gynecologist Elyse Lackie, who works at North York General Hospital's early pregnancy clinic and was not involved in developing the guidelines, says emergency departments are designed to treat severe, potentially life-threatening illness or injury quickly. "But early pregnancy loss sometimes is not an acute situation, it's something that's unfolding over days to even weeks," Lackie said. That's why those experiencing early pregnancy loss sometimes have to wait for hours at the emergency department, she said, while an early pregnancy assessment clinic is more ideal. "We provide nursing care, physician care, ultrasound lab care all in one place," Lackie said. "So we can help patients understand what is going on in their early pregnancy complications." Murray called the back-to-back pregnancy losses "soul crushing," and now turns to a support group for people who have experienced the same thing she did. "I'm doing a lot better now, but it wasn't an easy process to go through, unfortunately," she said.
CTV News
6 days ago
- CTV News
New national guidelines aim to help care for women experiencing early pregnancy loss
The Society of Obstetricians and Gynaecologists of Canada (SOGC) has issued new national clinical guidelines designed to improve the diagnosis and treatment of early pregnancy loss. The guideline, published today in the Journal of Obstetrics and Gynaecology of Canada , suggests best practices for identifying and managing miscarriages that occur in the first trimester. What's new in the guideline? The SOGC's guide spotlights the emotional and psychological toll of a miscarriage and calls for compassionate communication and trauma-informed care. Early loss occurs in about 15 per cent of pregnancies, the SOGC says. It says health-care providers should make patients aware that most early pregnancy loss is not preventable or treatable and that feelings of isolation and self-blame are common. Health-care providers are urged to validate patient experiences, provide clear explanations on next steps and offer referrals to mental health-care providers when needed. The guide also said clinicians should screen patients diagnosed with pregnancy loss for depression. The society is calling for more Early Pregnancy Assessment Clinics, or EPACs, within Canada, which serve as an alternative to emergency departments for women experiencing symptoms of pregnancy loss. The SOGC's updated recommendations give specific criteria for confirming early pregnancy loss using ultrasound and hormone testing. Clinicians are also advised to proceed with caution and ensure that viable pregnancies are not misdiagnosed. The goal is to avoid unnecessary delays or premature decisions that could lead to emotional distress or medical complications, the guide says.
Globe and Mail
6 days ago
- Globe and Mail
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
Johnson & Johnson JNJ has one of the most diverse revenue streams in the industry within the pharmaceutical division called Innovative Medicine. Under this segment, J&J markets several multi-million-dollar drugs covering a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension and infectious diseases. J&J's Innovative Medicine unit is showing a growth trend. The segment's sales rose 4.4% in the first quarter of 2025 on an organic basis despite the loss of exclusivity (LOE) for its multi-billion-dollar product, Stelara, and the negative impact of the Part D redesign. A biosimilar version of J&J's multi-billion-dollar immunology drug, Stelara, was launched in certain European markets for some indications in July 2024. Several biosimilar versions of Stelara are expected to be launched in the United States in 2025, according to patent settlements and license agreements. Amgen AMGN launched the first Stelara biosimilar, Wezlana, in January 2025, while Teva launched Selarsdi in February 2025. Stelara biosimilar competition is expected to accelerate throughout 2025 as the number of biosimilar entrants increases. Stelara sales are expected to come down from almost $11 billion in 2023 to around $2.9 billion in 2027, per our estimates. However, despite Stelara LOE, J&J expects growth in the Innovative Medicine segment in 2025 to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada as well as new cancer drugs like Carvykti, Tecvayli and Talvey, and new indications for Tremfya and Rybrevant. J&J expects to generate more than $57 billion in sales in the Innovative Medicine segment in 2025. It expects the Innovative Medicine business to grow 5-7% from 2025 to 2030. J&J Key Competitors Immunology and oncology are J&J's key areas. Other large drugmakers holding a strong presence in the oncology market are Novartis, AstraZeneca, AbbVie ABBV, Merck, Bristol-Myers, Roche and Pfizer PFE. In immunology, AbbVie, Amgen, Sanofi, AstraZeneca and Pfizer hold a strong position. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 10.4% in the year-to-date period compared with an increase of 4.0% for the industry. From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.58 forward earnings, slightly lower than 15.65 for the industry. The stock is also trading below its five-year mean of 15.76. The stock is cheaper than some other drugmakers like AbbVie, Lilly and Novo Nordisk. The Zacks Consensus Estimate for 2025 earnings has risen from $10.51 per share to $10.60 over the past 60 days, while that for 2026 has declined from $10.99 to $10.98 over the same timeframe. J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
